Several studies have proposed and shown the efficacy of inhibiting CHEK1 in TP53 wildtype and deleted in vitro and in vivo CLL cells, which could be considered as an additional combination treatment option [15,16,17]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.